Asterias Biotherapeutics Inc (AST) Stock Rating Reaffirmed by HC Wainwright
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Wednesday.
A number of other equities analysts also recently commented on the company. ValuEngine downgraded Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 4th. Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research note on Tuesday, October 10th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Asterias Biotherapeutics presently has an average rating of “Buy” and an average target price of $9.19.
Asterias Biotherapeutics (AST) opened at $2.55 on Wednesday. Asterias Biotherapeutics has a 52-week low of $2.00 and a 52-week high of $5.70.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.